CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 2.61: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.12BUSDvs all stocks (USD)
Revenue (TTM)
71.80MUSDvs all stocks (USD)
Profit Margin
-255.70%vs Biotechnology peers
Beta
-1.29xvs all stocks
52-Week Change
-26.05%vs all stocks
Market Capitalization
1.12BUSDvs all stocks (USD)
Enterprise Value
590.78MUSDvs all stocks (USD)
Forward P/E
-5.37xvs Biotechnology peers
Price to Sales (TTM)
15.60xvs Biotechnology peers
Price to Book (MRQ)
2.11xvs Biotechnology peers
Enterprise to Revenue
8.23xvs Biotechnology peers
Enterprise to EBITDA
-3.05xvs Biotechnology peers
Profit Margin
-255.70%vs Biotechnology peers
Operating Margin
-81.83%vs Biotechnology peers
Return on Assets (TTM)
-28.23%vs Biotechnology peers
Return on Equity (TTM)
-53.10%vs Biotechnology peers
Revenue (TTM)
71.80MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4030USDUpdated Jul 19, 2026Quarterly Revenue Growth
316.90%vs Biotechnology peers
Gross Profit (TTM)
-117.80MUSDvs all stocks (USD)
EBITDA (TTM)
-193.47MUSDvs all stocks (USD)
Net Income (TTM)
-183.59MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-184.01MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-125.72MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
42.73MUSDFY2025 · Dec 31, 2025Operating Income
-215.38MUSDvs all stocks (USD)
Pre-tax Income
-204.38MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-204.38MUSDFY2025 · Dec 31, 2025EBIT
-215.38MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-217.01MUSDFY2025 · Dec 31, 2025Research & Development
182.78MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
75.33MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.21USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.21USDFY2025 · Dec 31, 2025Basic Shares Outstanding
168.65MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
168.65MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-204.38MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-194.13MUSDFY2025 · Dec 31, 2025Free Cash Flow
-194.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
605.87MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-204.38MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
8.85MUSDFY2025 · Dec 31, 2025Stock-based Compensation
24.97MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
146.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-561.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-23.16MUSDFY2025 · Dec 31, 2025Capital Expenditures
-718.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-718.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
472.49MUSDFY2025 · Dec 31, 2025Shares Outstanding
192.34MSharesUpdated Jul 19, 2026Float Shares
90.11MSharesUpdated Jul 19, 2026Shares Short
20.90MSharesUpdated Jul 19, 2026Short Ratio
5.97daysvs all stocks
Short % of Shares Outstanding
13.48%vs all stocks
% Held by Insiders
15.88%vs all stocks
% Held by Institutions
82.69%vs all stocks
Total Cash (MRQ)
544.59MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.83USDUpdated Jul 19, 2026Total Debt (MRQ)
15.71MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0307xvs Biotechnology peers
Current Ratio (MRQ)
11.26xvs Biotechnology peers
Book Value per Share (MRQ)
2.76USDUpdated Jul 19, 2026Total Assets
638.50MUSDvs all stocks (USD)
Total Current Assets
614.81MUSDFY2025 · Dec 31, 2025Total Liabilities
120.14MUSDFY2025 · Dec 31, 2025Total Non-current Assets
23.68MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
25.08MUSDFY2025 · Dec 31, 2025Total Current Liabilities
95.06MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
602.07MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.28MUSDFY2025 · Dec 31, 2025Accounts Payable
15.70MUSDFY2025 · Dec 31, 2025Short-term Debt
8.36MUSDFY2025 · Dec 31, 2025Deferred Revenue
44.44MUSDFY2025 · Dec 31, 2025Long-term Debt
9.40MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.62BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.33BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
518.36MUSDvs all stocks (USD)
52-Week Low
5.02USDUpdated Jul 19, 202652-Week High
21.73USDUpdated Jul 19, 202652-Week Change
-26.05%vs all stocks
Beta
-1.29xvs all stocks
50-Day MA
6.20USDUpdated Jul 19, 2026200-Day MA
9.68USDUpdated Jul 19, 2026Avg 10-Day Volume
2.42MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.14MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.05USDUpdated Jul 19, 2026Other Income / Expense
11.01MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.61: safe zoneNotable
Altman Z-Score: 2.61
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EyePoint Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Capricor Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Savara Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Eos Energy Enterprises Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Fulcrum Therapeutics Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Pacific Biosciences of California, Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown